GlassScriptPhysician profile
Megan Duncan
NPI 1235190323
$899.96
in general payments reported to CMS, 2019-2025
19 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.12 · 2022: $203 · 2023: $265 · 2024: $270 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $189.51 | 2022-2025 | |
| Galderma Laboratories, L.P. | $145.58 | 2024-2025 | Dysport |
| Astrazeneca Pharmaceuticals LP | $103.09 | 2022-2024 | Tagrisso, Lynparza |
| Gilead Sciences, INC. | $63.39 | 2023 | Trodelvy |
| Genzyme Corporation | $53.19 | 2022 | |
| Pfizer INC. | $42.14 | 2021 | |
| Mirati Therapeutics, INC. | $41.19 | 2023-2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $38.39 | 2025 | |
| Astellas Pharma US INC | $32.73 | 2022 | |
| Genentech USA, INC. | $29.62 | 2023 | Rozlytrek, Tecentriq, Alecensa |
| Eisai INC. | $20.91 | 2022 | |
| Acrotech Biopharma INC. | $20.42 | 2024 | Beleodaq |
| Sumitomo Pharma America, INC. | $20.00 | 2023 | Orgovyx |
| Janssen Biotech, INC. | $19.18 | 2023 | Darzalex |
| Incyte Corporation | $18.98 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $17.88 | 2025 | Rytelo |
| Takeda Pharmaceuticals U.S.A., INC. | $16.57 | 2023 | Fruzaqla |
| Heron Therapeutics, INC. | $13.74 | 2022 | |
| Morphosys, US INC. | $13.45 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.